By elucidating the MK2-mediated control mechanism of p53 degradation in glioblastoma cells, this study proposes MK2 as a potential drug target for ~70% of glioblastomas carrying the intact TP53 gene. The gene discussed is MAPKAPK2; the disease is glioblastoma.